All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Jesus D. Gonzalez-Lugo, Montefiore Medical Center, presented the results from a phase II study evaluating the combination of eltrombopag and lenalidomide for the treatment of patients with symptomatic anemia and low- or intermediate-risk myelodysplastic syndrome. The MDS Hub is pleased to present a visual abstract summarizing the key safety and efficacy data from this study.
To download this visual abstract, click below.Download here
What is new for MDS with del(5q)?
During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo, University Hospital of Salamanca, Salamanca, ES. We asked,...
What is new for treating patients with low-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Pierre Fenaux, Université de Paris, Paris, FR, about the new advances for treating patients...
Subscribe to get the best content related to MDS delivered to your inbox